Noiiglutide

诺利糖肽

Report date: 2024/10/16 20:01:12
NME

Base Information

Drug NameNoiiglutide
Drug Alias NameHS-20004SHR-20004
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdJiangsu Haosen Medical Research Institute Co Ltd
Active IndicationsOverweightObesityDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A